Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

European Journal of Pharmacology
W Löscher, D Hönack

Abstract

The novel anticonvulsant drug ucb L059 ((S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide) was evaluated in several rodent models of partial and generalized seizures. Ucb L059 (27-108 mg/kg i.p.) increased the thresholds for tonic electroconvulsions and myoclonic and clonic seizures induced by timed i.v. infusion of pentylenetetrazol (PTZ), but was ineffective in the traditional maximal electroshock seizure and s.c. PTZ seizure tests in mice and rats in doses up to 500 mg/kg. The anticonvulsant potency of ucb L059 in seizure threshold tests was similar to that of standard drugs, such as valproate. In amygdala-kindled rats, ucb L059 exerted potent anticonvulsant activity against both focal and secondarily generalized seizures at doses of 13-108 mg/kg. The adverse effects of ucb L059 were quantitated in the open field and in standard tests for motor impairment, such as the rotarod and chimney tests. Ucb L059 exerted only minimal effects on behaviour, e.g. slight hyperactivity, and did not impair muscle activity in the rotarod test in doses up to 1700 mg/kg i.p. The data indicate that ucb L059 is an interesting new anticonvulsant agent with a broad spectrum of activity and high therapeutic index.

Associated Clinical Trials

References

Nov 10, 1992·European Journal of Pharmacology·A J GowerE Wülfert
Oct 1, 1991·Epilepsy Research·M R Trimble
Dec 1, 1991·Trends in Pharmacological Sciences·M Sarter
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Mar 1, 1972·Electroencephalography and Clinical Neurophysiology·R J Racine
Jan 1, 1984·Annals of Neurology·J O McNamara

❮ Previous
Next ❯

Citations

Nov 24, 1995·European Journal of Pharmacology·D G Margineanu, E Wülfert
Jun 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jarogniew J LuszczkiStanislaw J Czuczwar
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Misty SmithH Steve White
Apr 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·H Steve WhiteGrzegorz Bulaj
Apr 16, 2003·European Journal of Pharmacology·Doru Georg Margineanu, Henrik Klitgaard
Jul 25, 2003·European Journal of Pharmacology·Denis ArdidAlain Eschalier
Apr 23, 1997·European Journal of Pharmacology·G J SillsM J Brodie
Sep 3, 1998·European Journal of Pharmacology·H KlitgaardE Wülfert
Jul 13, 2001·Pharmacology & Therapeutics·P KwanM J Brodie
Mar 18, 2000·Pharmacology & Therapeutics·P N Patsalos
Feb 11, 2003·Epilepsy Research·Sharon C StrattonRussell M Hagan
Mar 26, 2003·Seizure : the Journal of the British Epilepsy Association·Jeffrey Cohen
Mar 26, 2003·Seizure : the Journal of the British Epilepsy Association·B Abou-KhalilM D Privitera
May 26, 2004·Seizure : the Journal of the British Epilepsy Association·Graeme J SillsMartin J Brodie
Dec 4, 2002·Epilepsia·Ali GorjiErwin-Joseph Speckmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.